CareDx Q2 revenue beats estimates; outlook lifted

CareDx

30/07/2026 21:10

Overview
Precision medicine diagnostics firm's Q2 revenue rose 52% yr/yr, beating analyst expectations
Adjusted EPS for Q2 beat analyst expectations
Company raised 2026 revenue and adjusted EBITDA guidance

Outlook
CareDx raises 2026 revenue guidance to $490 mln-$500 mln from $447 mln-$465 mln
Company lifts 2026 adjusted EBITDA forecast to $66 mln-$78 mln from $43 mln-$57 mln
CareDx says future results will exclude Lab Products segment after its divestiture

Result Drivers
TESTING SERVICES GROWTH - Co said higher Testing Services revenue was driven by ongoing adoption of molecular surveillance testing, favorable reimbursement, and increased testing activity across transplant programs
PATIENT AND DIGITAL SOLUTIONS - Co said Patient and Digital Solutions revenue rose due to continued growth in CareDx Pharmacy services and adoption of digital solutions for transplant monitoring
LAB PRODUCTS DIVESTITURE - Co recognized a full quarter of Lab Products revenue before divesting the segment at quarter end

Company press release: ID:nBw9xXLLSa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$132 mln
$114.04 mln (7 Analysts)
Q2 Adjusted EPS
Beat
$0.37
$0.23 (5 Analysts)
Q2 Adjusted Net Income
 
$20 mln
 
Q2 Net Income
 
$111 mln
 
Q2 Adjusted EBITDA
 
$25 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for CareDx Inc is $35.00, about 1.2% below its July 29 closing price of $35.41
The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 22 three months ago

Reuters Recommended Reads
July 28 - NeoGenomics Q2 revenue beats estimates, raises outlook
July 29 - Adaptive Biotechnologies Q2 revenue rises 22%, beats estimates
July 30 - Labcorp Q2 revenue slightly beats estimates, lifts 2026 outlook 

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)